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INTRODUCTION
Chronic bronchitis (СB) in children and adolescents is 
one of the most pressing problems in childhood pulmon-
ology [1-3]. CB is a multifactorial disease with a complex 
etiological structure, the development of which involves a 
large number of both internal and external risk factors [4]. 
One of the main risk factors for the development of CB in 
adolescence, and COPD in adults is tobacco-smoking [5,6]. 
Chronic Obstructive Pulmonary Disease (COPD) is a 
leading cause of morbidity and mortality worldwide that in-
duces an economic and social burden that is both substantial 
and increasing. COPD is currently the fourth leading cause 
of death in the world but is projected to be the 3rd leading 
cause of death by 2020. More than 3 million people died of 
COPD in 2012 accounting for 6 % of all deaths globally [6].
There are several reasons why environmental exposures in 
childhood are relevant to understanding the pathogenesis of 
chronic obstructive pulmonary disease (COPD). First, attenuation 
of lung growth due to air pollution in childhood is a risk factor for 
adult-onset respiratory disease. Second, there may be common cel-
lular and molecular mechanisms underlying impaired pulmonary 
innate host defenses in children exposed to air pollution, and the 
susceptibility to infection in COPD. Third, lung damage initiated 
in childhood may contribute to an emerging global health issue, 
namely, COPD due to tobacco smoke exposure [7]. 
According to the literature, the nature of the development 
of pathology, clinical manifestations and the course of diseases 
of the broncho-pulmonary system are determined not only by 
the duration of the influence of harmful factors, but also on 
the individual characteristics of the organism [8]. Therefore, 
an important internal risk factor for the development of CB 
is the genetic predisposition, with which the features of im-
munological reactivity, growth and development of the lungs 
are closely linked [8]. Today, the genetic mechanisms of the 
formation of COPD in adults have become the object of large-
scale research around the world [9,10,11]. But in childhood, 
the genetic risk factors for chronic respiratory diseases, except 
for bronchial asthma and cystic fibrosis, have practically not 
been studied. Thus, the study of the role of tobacco smoking in 
the development of CB in children and adolescents, analysis of 
molecular genetic factors can provide additional information on 
the mechanisms of its formation. It will allow to predict these 
conditions and develop methods of its prevention.
THE AIM
The aim of the investigation is to study the clinical features 
of the course of CB in adolescent smokers and to study the 
genetic risk factors for the development of COPD.
MATERIALS AND METHODS 
We examined 107 adolescents. All patients were divided into 
three groups. The Group 1 consisted of 40 adolescent smok-
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ers with chronic bronchitis (mean age – 17.5±0.2 years). The 
Group 2 consisted of 30 never-smokers adolescents with 
chronic bronchitis (mean age – 16.0±0.4 years). The Group 3 
(control group) consisted of 37 healthy adolescents-smokers 
(average age – 16.3±0.3 years). Verification of the diagnosis 
was carried out and based on standard criteria (a laborato-
ry-clinical and instrumental examination). 
The study included the collection of anamnesis and 
objective examination. The status of smoking among ad-
olescent smokers has been examined as a risk factor for 
the development of the disease with the calculation of the 
smoking index (SI was defined as number of cigarettes 
smoked per day multiplied by years smoked) and the 
indicator «pack/year» ((number of cigarettes smoked per 
day/20) × number of years smoked).
To achieve the aim, the MMP1 gene -1607 1G/2G 
(rs1799750) polymorphism, CYP1A1 gene T3801C 
polymorphism have been studied. Molecular genetic in-
vestigations were performed at the Institute of Hereditary 
Pathology, Academy of Medical Sciences of Ukraine. 
All statistical calculations were performed by means 
of Statistica v 10.0. The results were defined as means ± 
standard deviation (SD) and Me (Q25; Q75). Each of the 
SNPs in the five genes was analyzed for Hardy-Weinberg 
equilibrium (HWE) using a computer program for an-
alyzing genetic data «GeneExpert» (http://gen-exp.ru/
calculator_or.php). To determine the SNPs associated 
with the risk of CB, the frequencies of the genotypes of 
the three study groups were compared, and the odds ratio 
(OR) was calculated with a 95% CI. Statistical significance 
was defined as p<0.05.
RESULTS AND DISCUSSION 
The analysis of the tobacco smoking status showed that 
patients of the Group 1 compared to control were 2,0 times 
more likely to experience tobacco smoking (p<0,05), table 1. 
In addition, they smoked significantly more cigarettes per 
day than control (in 1,4 times respectively; p<0,05), had 
significantly higher values of SI (in 1,4 times respectively; 
*: significance of differences (p<0,05)
Figure 1. Clinical and anamnestic features of the course of chronic bronchitis in the examined adolescents
Table 1. Indicators of the tobacco smoking status in adolescent smokers, Me (Q25; Q75)
Indicator Group 1(n=40)
Control group  
(n=37) р
Age of the beginning of smoking, years 14,0(12,0; 14,0)
14,0
(13,0; 15,0) р>0,05
Experience of active tobacco smoking, years 4,0(3,0; 5,5)
2,0
(1,0; 2,0) р<0,05
Number of smoked cigarettes per day, pieces 10,0(10,0; 13,5)
7,0
(5,0; 10,0) р<0,05
Smoking index 120,0(120,0; 162,0)
84,0
(60,0; 120,0) р<0,05
«Pack/year» 2,0(1,5; 3,25)
0,5
(0,25; 1,0) р<0,05
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p<0,05) and the indicator “Pack/year” (4,0 times; p<0,05).
Comparison of clinical features of the course of bron-
chitis has shown that in patients of  Group 2 the average 
length of the disease was significantly superior to those in 
Group 1 and was (6.9 ± 0.8) years vs (3.2 ± 0.2) respectively 
(р<0,05), figure.1.
The number of exacerbations per year in patients of 
Group 1 and Group 2 practically did not differ and was 
(3.9±0.1) vs (3.9±0.3) (p>0.05). However, in patients of 
Group 1, the duration of exacerbations was significantly 
higher than in patients of the Group 2 (4.1 ± 0.1 weeks 
versus 3.6 ± 0.1 weeks) (p <0.05). (р<0,05).
It was found that in adolescent smokers of Group 1, the 
duration of exacerbations significantly differed, and the 
frequency of exacerbations correlated with the number of 
smoked cigarettes per day (r=+0,56; p<0,05), SI (r=+0,56; 
p<0,05) and the “Pack-year” (r=+0,59; p<0,05).
The analysis of clinical data showed that the course of CB 
in adolescent smokers in the period of clinical remission was 
characterized by complaints of permanent (65.0 % vs 12.5 %; 
p<0,05) low-productive cough (95.0 % vs 18.7 %; p<0,001) 
predominantly in the morning (90.0 % vs 25.0 %; p<0,001). 
Periods of exacerbation in patients of Group 1 compared to 
Group 2, according to primary medical documentation, were 
characterized by the absence of seasonality (90.0 % vs 25.0 %; 
p<0,001), complaints of low-productive cough (80.0 % vs 31.2 
%; p<0,01) with predominantly mucosal sputum (85.0 % vs 
25.0 %; p<0,001), dyspnea during exercise (60.0 % vs 25.0 %; 
p<0,05) and prevalence during auscultation of dry wheezing 
(70.0 % vs 6.3 %; p<0,05). In patients of Group 2 were more 
likely to hear moist rales (56.2 % versus 20.0 %; p<0.05) and 
mixed rales (37.5 % vs 10.0 %; p<0,05) at auscultation.
The results of the molecular genetic study revealed a 
statistically significant difference between Group 1 and 
control, figure 2.
When comparing the frequencies of the genotypes of the 
MMP1 gene -1607 1G/2G (rs1799750) polymorphism in 
patients of Group 1 compared with control, the frequen-
cy of the homozygous genotype 2G/2G was significantly 
higher (66.7 % vs 6.7 %; OR=28.00; 95 % СІ (2.82-277.97)). 
In the control group, the heterozygous genotype 1G / 2G 
is more common (73.3 % vs 33.3 %; OR=0.18; 95 % CІ 
(0.04-0.87)).
The analysis of the frequency distribution of genotypes 
of the CYP1A1 gene showed a significant increase in the 
proportion of homozygous TT carriers in the control 
group compared to Group 1 (93.3 % vs 53.3 %, χ2=6.21, 
р<0.05), figure 3.
*: significance of differences (p<0,05)
Figure 3. Genotype frequencies of CYP1A1 gene T3801C polymorphism in the studied groups
*: significance of differences (p<0,05)
Figure 2. Genotype frequencies of MMP1 gene -1607 1G/2G (rs1799750) polymorphism in the studied groups
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Thus, the molecular genetic study revealed the associa-
tion of the 2G/2G genotype of MMP1 gene -1607 1G/2G 
(rs1799750) polymorphism (OR=28.00; 95 % CI (2.82-
277.97)) with the development of chronic bronchitis in 
adolescent smokers. The TT genotype of CYP1A1 gene 
T3801C polymorphism (OR=0.08; 95 % CI (0.01-0.79)) 
may be considered as a possible sustainability factor for 
the development of chronic bronchitis in adolescent 
smokers.
CONCLUSIONS 
1.  Tobacco smoking leads to the development of chronic 
bronchitis as early as adolescence and affects its course, 
increasing the frequency and duration of exacerbations.
2.  The 2G/2G genotype of MMP1 gene -1607 1G/2G 
(rs1799750) polymorphism can be considered as a risk 
factor for the development of chronic bronchitis in 
Ukrainian adolescent smokers and chronic obstructive 
pulmonary disease in the future.
3.  The presence of TT genotype of CYP1A1 gene T3801C 
polymorphism in adolescent smokers can be considered 
as a possible marker of resistance to chronic diseases of 
the respiratory system. 
4.  The study of the genes for chronic obstructive pulmonary 
disease in childhood and adolescence will contribute to 
the early detection of high-risk patients for the formation 
of this pathology, which will make it possible to carry 
out the necessary preventive measures and to maximize 
postponement of the disease. 
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